Abbott selects two of Celera's cancer targets for development

By Lisa Kerner

Erie, Pa., Feb. 6 - Celera Genomics Group said that Abbott Laboratories has selected two Celera antigen targets for further investigation and potential therapeutic development.

Abbott now has a total of four targets under investigation from its strategic collaboration with Celera to develop therapies for the treatment of cancer, according to a company news release.

"This is further validation of the value our proteomics platform has yielded in discovering and validating targets in pancreatic, lung, colon, breast, gastric, prostate and renal cancers," Kathy Ordonez, president of Celera, said in the release. "We now have five antigens in the research pipeline with our partners, and we are working to move additional targets forward for therapeutic development through current and future collaborations."

The collaboration encompasses the development of therapeutic antibodies and small molecule drugs against over-expressed cell-surface proteins that have been associated with cancer. Celera would share any financial returns resulting from commercialization, or alternately be paid milestones and royalties on successful therapies. Abbott has responsibility for the commercialization of jointly funded collaboration products, while Celera certain diagnostic rights associated with selected targets.

Celera, an Applera Corp. business, discovers, develops and commercializes diagnostic products and validates drug targets and pharmacogenomic markers. The company is based in Rockville, Md.

Abbott is a health care products company based in Abbott Park, Ill.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.